CA2841178C - Notch pathway signaling inhibitor compound - Google Patents
Notch pathway signaling inhibitor compound Download PDFInfo
- Publication number
- CA2841178C CA2841178C CA2841178A CA2841178A CA2841178C CA 2841178 C CA2841178 C CA 2841178C CA 2841178 A CA2841178 A CA 2841178A CA 2841178 A CA2841178 A CA 2841178A CA 2841178 C CA2841178 C CA 2841178C
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- pharmaceutically acceptable
- hydrate
- acute lymphoblastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US61/512,016 | 2011-07-27 | ||
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| US61/560,486 | 2011-11-16 | ||
| PCT/US2012/047100 WO2013016081A1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2841178A1 CA2841178A1 (en) | 2013-01-31 |
| CA2841178C true CA2841178C (en) | 2016-12-20 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2841178A Active CA2841178C (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Country Status (36)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110506A2 (en) * | 2013-01-14 | 2014-07-17 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| SG10201913587WA (en) | 2016-02-05 | 2020-02-27 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| KR102418765B1 (ko) * | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102418766B1 (ko) * | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 |
| US10688104B2 (en) | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| US20190209581A1 (en) * | 2016-08-31 | 2019-07-11 | Eli Lilly And Company | Dosage regimen for treatment of solid tumors |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| DK3552017T3 (da) | 2016-12-09 | 2022-05-16 | Denali Therapeutics Inc | Forbindelser, der er anvendelige som ripk1-inhibitorer |
| JP2020507605A (ja) | 2017-02-17 | 2020-03-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法 |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| MX2020011826A (es) * | 2018-05-06 | 2021-01-15 | Ayala Pharmaceuticals Inc | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |
| MX2021003773A (es) | 2018-10-02 | 2021-07-16 | Frequency Therapeutics Inc | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. |
| BR112021020141A2 (pt) | 2019-04-08 | 2021-12-21 | Frequency Therapeutics Inc | Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva |
| WO2023137035A1 (en) | 2022-01-12 | 2023-07-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199901343T2 (xx) * | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| AU4710199A (en) * | 1998-06-22 | 2000-01-10 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| WO1999067219A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| ATE402934T1 (de) | 2003-02-04 | 2008-08-15 | Hoffmann La Roche | Malonamidderivate als gamma-secretaseinhibitoren |
| AU2004270361B2 (en) | 2003-09-09 | 2009-06-25 | F. Hoffmann-La Roche Ag | Malonamide derivatives blocking the activity of gama-secretase |
| PT1673347E (pt) | 2003-10-06 | 2015-11-02 | Hoffmann La Roche | Derivados de dibenzo-azepina e benzo-diazepina substituídos, úteis como inibidores de secretase gama |
| KR101169628B1 (ko) | 2006-03-27 | 2012-07-30 | 에프. 호프만-라 로슈 아게 | 감마 세크레테아제 저해제로서의 말론아미드 유도체 |
| AU2008209861B2 (en) * | 2007-02-02 | 2012-08-09 | F. Hoffmann-La Roche Ag | 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives |
| MA33076B1 (fr) | 2008-01-11 | 2012-03-01 | Hoffmann La Roche | Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en not_active Ceased
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2736920B1 (en) | Notch pathway signaling inhibitor compound | |
| EP3283079B1 (en) | Targeted treatment of leiomyosarcoma | |
| KR20210098960A (ko) | Helios의 소분자 분해제 및 사용 방법 | |
| CA2863673A1 (en) | 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors | |
| KR102640463B1 (ko) | 피리미딘 화합물 또는 그 염 | |
| CN114437116B (zh) | 杂环化合物及其制备方法、药物组合物和应用 | |
| CN118420620A (zh) | 杂环化合物 | |
| CN115768757B (zh) | Cd206调节剂及其用途和制备方法 | |
| KR20210135521A (ko) | 피롤로피라졸 유도체 | |
| TW201124398A (en) | Quinazoline derivatives | |
| WO2025090605A9 (en) | Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19 | |
| CN114555597B (zh) | 异柠檬酸脱氢酶（idh）抑制剂 | |
| NZ618891B2 (en) | Notch pathway signaling inhibitor compound | |
| HK1194086B (en) | Notch pathway signaling inhibitor compound | |
| HK1251166B (en) | Targeted treatment of leiomyosarcoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251014 |
|
| H13 | Ip right lapsed |
Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE Effective date: 20260302 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |